Share Price Information for Glaxosmithkline (GSK)
GLAXOSMITHKLINE PLC ORD 25P
Glaxosmithkline is listed in the
FTSE 100,
FTSE All-Share,
FTSE 350Glaxosmithkline is part of the
Pharmaceuticals & Biotechnology sectorGlaxosmithkline has a share of around 5% of the world’s pharmaceutical market, aiming to tackle 3 of the ‘priority’ diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.

Price
1742.00

Bid
1744.50

Ask
1745.00

Change
-1.75%

-31.00

Volume
7,620,228

Open
1,752.50

High
1,759.50

Low
1,733.50

Close
1,773.00

Currency
GBX
| Currency |
Issue Country |
Shares in Issue |
Market Capitalisation |
Market Size |
| GBX |
GB |
4,927.46m
|
£85,836.34m |
2,000 |
| 52 Week High |
1,773.00 |
52 Week High Date |
22-MAY-2013 |
| 52 Week Low |
1,314.00 |
52 Week Low Date |
19-NOV-2012 |
| # Trades |
Vol. Sold |
Vol. Bought |
PE Ratio |
Earnings |
Dividend |
Yield |
| 8,404 |
5,082,748 |
2,488,009 |
18.751 |
92.90 |
74.00 |
4.25 |
23-May-13
16:35:01
1,742.00
1,648
Sell*
1,744.50
1,745.00
28.71k
O

Trade Type:
Ordinary
Deletion
23-May-13
16:35:01
1,742.00
3,007
Sell*
1,744.50
1,745.00
52.38k
O

Trade Type:
Ordinary
Deletion
23-May-13
16:35:05
1,742.00
2,241,045
Sell*
1,742.00
1,743.00
39.039M
UT

Trade Type:
Uncrossing Trade
*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.
View more Glaxosmithkline trades >>| Directors Deals for Glaxosmithkline (GSK) |
| Trade Date | Action | Notifier | Price | Currency | Amount | Holding |
|---|
| 16-May-13 | Transfer To |  Sir Andrew P Witty held the position of CEO at GlaxoSmithKline at the time of this trade. Sir Andrew P Witty | 1723.58 | GBX | 670 | 0 |
| 16-May-13 | Transfer From |  Sir Andrew P Witty held the position of CEO at GlaxoSmithKline at the time of this trade. Sir Andrew P Witty | 1723.64 | GBX | 664 | 0 |
| 16-May-13 | Transfer To |  Sir Andrew P Witty held the position of CEO at GlaxoSmithKline at the time of this trade. Sir Andrew P Witty | 0 | | 1,000 | 0 |
View more Glaxosmithkline directors dealings >>Date/Time
Author
Subject
Share Price†
Opinion
Wed 07:23
NumptyClub
RE: FTSE P/E 14.7
1,742.00
Hold
Interesting post, thanks.
16 May '13
driftking27
FTSE P/E 14.7
1,707.50
Hold
Remember you are trying to beat the FTSE on a P/E, and also keep risk to a mimum, and dividends mean nothing. If you invest in a high dividend player like this and the markets plummet on bad news, this share goes down with them as well. It will generally take twice as long for this to steam ahead as others to get back to the same footing as before.
16 May '13
driftking27
accumulate shares
1,707.50
Hold
If you hold this share, like I have for 4.5years, accumulate shares on a dip if you like GSK. It is an expensive stock to peers, and I can only see single digit growth. I own Novartis ADR for nearly 6years and things only get better with this bemometh, also JNJ and very small holding of 250 in AZN.
12 May '13
chris47
barchart
1,670.00
Hold
http://www.barchart.com/opinions/stocks/GSK.LS
10 May '13
chris47
1688
1,670.00
Strong Buy
back at 1688 if you include the divi
10 May '13
chris47
sweet news
1,670.00
Strong Buy
"The FDA approval of BREO ELLIPTA brings an important inhaled, once-daily maintenance therapeutic option to COPD patients and doctors across the United States," said Rick E Winningham, Chief Executive Officer of Theravance. "After more than a decade of joint respiratory research and development, the approval is a very important milestone for Theravance and GSK."
†Share prices shown are taken at time of message posting.
Thread ViewView more share chat for Glaxosmithkline (GSK) >>Please
Login or
Register to post messages
Request your Free brochures on share dealing, spread betting and CFDs